Cytokinetics (CYTK)Director sold ~$405K

~$405K

Approx. value · 6,757 sh @ $60.00

9,778

Holds after · shares reported

Traded

Oct 6, 2025

Filed

Oct 6, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 11, 2025CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
2. Jun 17, 2025CongressDisclosed sale of CYTK — reported range $1,001 - $15,000
3. Aug 15, 2025InsiderCEO sold ~$192K of CYTK shares in the open market
4. Aug 19, 2025InsiderOfficer sold ~$77K of CYTK shares in the open market
5. Sep 2, 2025Insider · 3 peopleInsiders: 3 sales (~$686K)
6. Sep 9, 2025InsiderOfficer sold ~$103K of CYTK shares in the open market
7. Sep 15, 2025InsiderCEO sold ~$249K of CYTK shares in the open market
8. Sep 16, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
9. Sep 23, 2025InsiderOfficer sold ~$99K of CYTK shares in the open market
10. Sep 30, 2025InsiderDirector sold ~$369K of CYTK shares in the open market
11. Oct 6, 2025 · this disclosureInsiderDirector sold ~$405K of CYTK shares in the open market

What came next

1. Oct 7, 2025InsiderOfficer sold ~$121K of CYTK shares in the open market
2. Oct 9, 2025CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
3. Oct 16, 2025InsiderCEO sold ~$300K of CYTK shares in the open market
4. Oct 21, 2025InsiderOfficer sold ~$123K of CYTK shares in the open market
5. Oct 27, 2025InsiderDirector sold ~$257K of CYTK shares in the open market
6. Oct 30, 2025InsiderCEO sold ~$314K of CYTK shares in the open market
7. Nov 4, 2025InsiderOfficer sold ~$137K of CYTK shares in the open market
8. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
9. Nov 11, 2025InsiderDirector sold ~$337K of CYTK shares in the open market
10. Nov 13, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 13, 2025, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Jeffrey J. Hessekiel, pursuant to which Mr. Hessekiel has agreed to serve as the Company’s Executive Vice President, Chief Legal and Administrative Officer, effective as of November 14, 2025 (the “Start Date”).”
11. Nov 18, 2025InsiderOfficer sold ~$146K of CYTK shares in the open market
12. Nov 19, 2025InsiderDirector sold ~$324K of CYTK shares in the open market
13. Dec 1, 2025Insider · 2 peopleInsiders: 2 sales (~$2.0M)
14. Dec 2, 2025Insider · 2 peopleInsiders: 2 sales (~$700K)
15. Dec 5, 2025InsiderOfficer sold ~$3.46M of CYTK shares in the open market
16. Dec 8, 2025InsiderOfficer sold ~$69K of CYTK shares in the open market
17. Dec 16, 2025InsiderOfficer sold ~$135K of CYTK shares in the open market
18. Dec 22, 2025InsiderDirector sold ~$1.32M of CYTK shares in the open market
19. Dec 29, 2025InsiderOfficer sold ~$113K of CYTK shares in the open market
20. Jan 2, 2026Insider · 1 personInsiders: 2 sales (~$113K)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cytokinetics

For Cytokinetics, OQRO holds 18 insider filings (SEC Form 4 or Form 144) and 11 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.

Other recent filings by Edward M. Md Kaye, Director

• SEC Form 4 at Cytokinetics (CYTK)Jun 1, 2026
• SEC Form 4 at Cytokinetics (CYTK)Dec 2, 2025
• SEC Form 4 at Cytokinetics (CYTK)Nov 12, 2025
• SEC Form 4 at Cytokinetics (CYTK)Sep 30, 2025
• SEC Form 4 at Stoke Therapeutics (STOK)Sep 3, 2025

The full history of Edward M. Md Kaye, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cytokinetics

• SEC Form 4Oct 6, 2026
• SEC Form 4Sep 28, 2026
• SEC Form 4Sep 22, 2026
• SEC Form 4Sep 15, 2026
• SEC Form 4Sep 15, 2026
• SEC Form 4Sep 15, 2026

Everything OQRO holds on this company is on its CYTK page.